The retraction of a clinical trial by Dr. Sabine Hazan exploring treatments for COVID-19 has raised renewed questions about undisclosed ties between researchers and pharmaceutical investors. The studies, which had been published in peer-reviewed journals, were withdrawn after concerns surfaced regarding data integrity and conflicts of interest. According to the retraction notices, the authors failed to disclose financial relationships with pharmaceutical investors. The case parallels earlier retractions where financial relationships remained hidden from readers and oversight bodies. Background of the Clinical Trial Dr. Hazan conducted a clinical trial testing a combination of hydroxychloroquine and zinc as a treatment for COVID-19.…

Newswire

Features

The Latest